Venture capital’s leading firms demonstrated appetite for emerging digital technologies during the past year, deploying $33.1 billion across 874 pre-seed, seed, and early-stage deals tracked by PitchBook’s Emerging Tech Indicator (ETI). While deal volume stayed below the five-year average, the sheer dollar amount marked a new high, underscoring a clear shift toward larger, high-conviction bets in artificial intelligence and healthcare.
In the fourth quarter alone, the top 15 VCs—selected for their proven track record in exits and valuations—participated in 225 transactions worth $10.5 billion.
This quarterly figure matched the peaks of the 2021–2022 boom, even as total deal counts remained disciplined.
Three standout companies each raised $2 billion, accounting for nearly one-fifth of annual ETI capital and illustrating the market’s willingness to back frontier AI laboratories and ambitious healthcare platforms at unprecedented scale.
Artificial intelligence continued its commanding lead.
AI and machine-learning deals represented 51.6% of Q4 activity and over half the capital deployed, far outpacing the broader venture market where AI accounted for just 34.2% of deals.
Annual AI investment reached $14.2 billion across 186 rounds, with mega-financings such as Reflection AI’s $2 billion Series B (valuing the company at $8 billion post-money) and eye-popping seed rounds for humans& and Unconventional AI both hitting $4.5 billion valuations dominating headlines.
Vertical AI applications in accounting, medical diagnostics, and enterprise automation also attracted steady capital, though competition from incumbents remains intense.
Other sectors showed renewed momentum.
Fintech captured $2.1 billion on the year, healthtech and wellness $2.1 billion, and climate tech $1.9 billion.
Biotechnology staged a notable rebound, posting its strongest quarterly activity in years with $657 million across 15 deals—many involving clinical-stage assets and AI-driven drug discovery.
Cybersecurity saw record quarterly funding of $643 million, fueled by AI-powered defense platforms commanding average pre-money valuations of $273 million.
Valuations across ETI companies remained sharply elevated.
Seed pre-money medians sat $13.7 million above broader venture benchmarks, while early-stage medians were $165.6 million higher.
This premium reflects both the quality of top-tier backing and the market’s confidence in scalable, AI-native models.
Performance metrics reinforce the strategy’s effectiveness.
ETI-backed startups have achieved a 9.2% exit rate—nearly double the overall venture average—and a 4.0% unicorn rate compared with just 0.5% across all VC-funded companies.
Geography tells another story: 75% of Q4 deals were U.S.-based, with non-U.S. activity slipping and China essentially frozen out due to regulatory and geopolitical headwinds.
PitchBook analysts note that the ETI now represents 21% of all seed and early-stage venture investment—up from 13.5% in the prior five-year period—signaling deepening concentration among elite managers.
While diversification has narrowed, the data suggest that disciplined capital allocation toward transformative technologies is yielding superior returns.
As 2026 continues to unfold, the report from PitchBook points to continued emphasis on frontier AI labs, AI-integrated healthcare, and resilient cybersecurity solutions. With larger checks and higher valuations becoming the norm, the emerging-tech landscape appears poised for further consolidation around a select group of high-potential innovators.
